Wixela 500 refers to a specific dosage of Wixela Inhub, a medication used for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) [1].
What is Wixela Inhub?
Wixela Inhub is an inhaler device that delivers a combination of fluticasone propionate and salmeterol [1]. Fluticasone propionate is an inhaled corticosteroid that reduces inflammation in the airways, while salmeterol is a long-acting beta2-adrenergic agonist (LABA) that helps to keep the airways open [2]. It is indicated for patients with COPD who are already receiving treatment for their condition but require additional medication to manage their symptoms [1].
How does Wixela 500 work?
The "500" in Wixela 500 indicates the dosage of fluticasone propionate delivered by the inhaler. Each inhalation delivers 500 micrograms of fluticasone propionate and 50 micrograms of salmeterol [1][3]. The fluticasone propionate component works by suppressing the release of inflammatory mediators, thereby reducing swelling and mucus production in the lungs. Salmeterol works by relaxing the smooth muscles around the airways, which helps to prevent them from constricting and makes breathing easier [2].
When does Wixela Inhub's patent expire?
The patent landscape for medications can be complex, with multiple patents covering different aspects of the drug and its delivery device. Information on specific patent expiration dates for Wixela Inhub can be found through specialized databases. DrugPatentWatch.com provides detailed information on drug patents and their expiration timelines [4].
What are the alternatives to Wixela Inhub?
Other medications for COPD may involve different combinations of inhaled corticosteroids, long-acting bronchodilators (LABAs or long-acting muscarinic antagonists - LAMAs), or triple therapy combining all three classes. These alternatives may differ in their active ingredients, dosages, and delivery devices. Patients should discuss treatment options with their healthcare provider to determine the most suitable alternative based on their individual needs and medical history [2].
What are the risks of using Wixela Inhub?
As with any medication, Wixela Inhub carries potential risks and side effects. These can include an increased risk of pneumonia in patients with COPD, oral thrush, hoarseness, and throat irritation [1]. Long-term use of inhaled corticosteroids may also be associated with a decrease in bone mineral density and potential effects on growth in children, though the latter is not typically a concern for adult COPD patients. Salmeterol, like other LABAs, may increase the risk of asthma-related death when used alone in patients with asthma, but this risk is not seen when it is used in combination with an inhaled corticosteroid for COPD [2].
How does Wixela Inhub compare to other COPD inhalers?
Wixela Inhub is a combination inhaler containing an inhaled corticosteroid and a LABA. Other COPD inhalers may contain only a bronchodilator (LABA or LAMA), or a combination of a LABA and a LAMA. Triple therapy inhalers combine an inhaled corticosteroid, a LABA, and a LAMA. The choice of inhaler depends on the severity of the COPD, the patient's symptom control, and their response to different medications [2].
Sources:
[1] https://www.wixelahcp.com/
[2] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treatment
[3] https://www.drugs.com/wixela-inhub.html
[4] https://drugpatentwatch.com/